Skip to main content

Market Overview

Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study


Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO) have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).

  • The companies will conduct a Phase 2b study of Novo Nordisk's semaglutide and a fixed-dose combination of Gilead's cilofexor and firsocostat, alone and in combination in people with compensated cirrhosis due to NASH.
  • The four-arm study in approximately 440 patients will evaluate the treatments' impact on liver fibrosis improvement and NASH resolution. Patient recruitment will start in the second half of 2021.
  • This new Phase 2b study builds on results from a Phase 2a proof-of-concept study presented at Liver Meeting Digital Experience in November last year investigating semaglutide, alone and in combination with cilofexor and firsocostat, in 108 people with NASH and mild to moderate fibrosis.
  • The study met its primary endpoint, demonstrating that all regimens were well tolerated over 24 weeks. The most common adverse events were gastrointestinal. Across all groups, 5–14% of people discontinued any trial treatment due to adverse events.
  • Also, post-hoc analyses of exploratory efficacy endpoints assessing liver health biomarkers at 24 weeks showed statistically significant improvements in hepatic steatosis and liver injury in the combination treatment arms versus semaglutide alone.
  • Price Action: NVO shares are trading 0.81% lower at $71.2 in premarket on the last check Thursday, while GILD shares closed 0.6% higher at $64.42 on Wednesday.

Related Articles (GILD + NVO)

View Comments and Join the Discussion!

Posted-In: nonalcoholic steatohepatitisBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at